bcbstx glp-1 coverage Perspectives from employers on the costs and issues associated with covering agonists for weight loss The GLP-1 Access Gap: Mapping – The Employer Shift in Obesity

SAR425899 and MEDI0382 (also named cotadutide) have undergone Phase II clinical trials [78, 79]

In real-world data, GLP-1RAs differ in clinical indications, uptake over time, adherence rate, typical treatment duration, dose escalation, and patient selection, all of which can introduce residual confounding and channeling bias ( Notably, the observed reductions in the odds of substance use disorders, including a 74% decrease in the odds of AUD, a 69% reduction for OUD, a 68% reduction for NUD, and a 75% reduction for CUD, among GLP-1 RA users were consistent with emerging preclinical and clinical studies showing that GLP-1 RA modulates reward pathways in the brain to reduce SUD (34)

Skin and hair health Peptides like sermorelin may help slow or even reverse some of the visible effects of aging on skin

10.1001/archpsyc.56.12.1135 Arch